Specialty
Clinical
Quality Improvement
Publications
Partners
Kidney Carcinoma
>
Latest News
Lenvatinib/Pembrolizumab Generates Lasting Responses in Advanced Kidney Cancer
By Jordyn Sava
November 6th 2023
The duration of response was 39.2 months among patients with 1 metastatic site treated in the combination arm vs 29.5 months for patients given sunitinib.
More News
Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective
January 18th 2023A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.
